The Cancer Moonshot Task Force has just released its 5 year plan
for implementing President Obama's "Cancer Moonshot"
program ("Report"). The initiative, announced
during President Obama's 2016 State of the Union Address, is a
national effort to dramatically accelerate efforts to prevent,
diagnose and treat cancer that take advantage of recent advances in
molecular medicine and information sciences. This initiative is
unique in its emphasis on public and private collaboration:
"The Cancer Moonshot aims to realize this promise by
leveraging public and private efforts focused on building a system
in which patients, researchers, and clinicians can seamlessly share
information on treatments and outcomes to accelerate research,
guide treatment decisions, and improve cancer outcomes for people
across the Nation, and ultimately the world."
Report at page 2.
Five Goal Approach
The Report, authored by the Moonshot Task Force, noted the need
to have an organizational framework for addressing and uniting
efforts to reach the goal of improving cancer diagnosis and
therapy. Five goals emerged, each of which is noted to be critical
to the overall mission, but also intended to build on and augment
the success of the other goals. Report at page 5.
Strategic Goal 1: Catalyze New Scientific
New scientific breakthroughs will be accelerated by: 1)
promoting interdisciplinary approaches for elucidating the
biological mechanism underlying cancer onset and treatment; 2)
aligning research and care as a seamless and iterative process; and
3) maximizing the collection and research use of longitudinal data
Strategic Goal 2: Unleash the Power of Data
A stated goal of the Task Force is to maximize access to and
usability of data now available due to advances in genomic
information and health record information. This will be achieved
by: 1) enabling a seamless data environment; 2) supporting open
publication and storage platforms; and 3) developing a workforce
that can take advantage of the open and connected environment.
Strategic Goal 3: Accelerate Bringing New Therapies to
New effective therapies are the ultimate goal of the
President's initiative. The Task Force seeks to remove
impediments by: 1) finding efficiencies in regulatory review and
licensing processes; 2) enhance data sharing and incentivize
pre-competitive collaborations; and 3) strengthen oncology clinical
Strategic Goal 4: Strengthen Prevention and
Cancer prevention and diagnosis can be strengthened by: 1)
promoting public access to health programs, policies and outreach;
2) gaining a better understanding of the environmental determinants
of cancer; and 3) enhancing cancer screening and testing.
Strategic Goal 5: Improve Patient Access and Care
Strategic goal 5 seeks to build on the improved access to health
care provided by the Affordable Care Act. The Task Force seeks to
identify areas with the greatest potential for meaningful patient
impact by: 1) improve efficiencies of current programs; 2) improve
cancer prevention, treatment and quality of care by applying
current knowledge into workable policies; and 3) ensuring each
patient receives quality care.
Creating New Paradigms
The Report sets out a blueprint with a series of activities to
accelerate gains for cancer diagnosis and therapy – that is,
to achieve ten years of progress in five. The Report summarizes the
aspirations, conceptual and practical, that can be achieved:
"Ultimately, through the creation of new paradigms for
generating, sharing, and integrating research and clinical data to
enhance patient care, the Cancer Moonshot can accelerate the
delivery of effective cancer prevention strategies, diagnostics,
and treatments to patients in communities around the
Report at page 29.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
A March 2 article in Bloomberg BNA's Privacy Law Watch and other publications, "Privacy and Security Audits May Be Moving From Education to Enforcement," reported that the Department of Health and Human Services' Office for Civil Rights' (OCR's) ongoing HIPAA privacy and security audits may be shifting focus from provider education to enforcement.
It's been a couple of months since the dust has settled from FDA's October 26, 2016 approval of Mylan Pharmaceuticals Inc.'s ANDA 078276 for a generic version of Daiichi Sankyo Inc.'s BENICAR Tablets...
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).